GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fate Therapeutics Inc (NAS:FATE) » Definitions » Cyclically Adjusted Book per Share

FATE (Fate Therapeutics) Cyclically Adjusted Book per Share : $3.99 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Fate Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Fate Therapeutics's adjusted book value per share for the three months ended in Mar. 2025 was $2.517. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.99 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Fate Therapeutics's average Cyclically Adjusted Book Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-07-07), Fate Therapeutics's current stock price is $1.06. Fate Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $3.99. Fate Therapeutics's Cyclically Adjusted PB Ratio of today is 0.27.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Fate Therapeutics was 15.89. The lowest was 0.19. And the median was 1.22.


Fate Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Fate Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics Cyclically Adjusted Book per Share Chart

Fate Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.22 3.70 3.91

Fate Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.79 3.84 3.88 3.91 3.99

Competitive Comparison of Fate Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Fate Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fate Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Fate Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fate Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.517/134.9266*134.9266
=2.517

Current CPI (Mar. 2025) = 134.9266.

Fate Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 1.785 100.684 2.392
201509 1.567 100.392 2.106
201512 1.325 99.792 1.791
201603 1.065 100.470 1.430
201606 0.801 101.688 1.063
201609 0.743 101.861 0.984
201612 1.767 101.863 2.341
201703 1.542 102.862 2.023
201706 1.333 103.349 1.740
201709 1.103 104.136 1.429
201712 1.466 104.011 1.902
201803 1.230 105.290 1.576
201806 0.971 106.317 1.232
201809 2.696 106.507 3.415
201812 2.480 105.998 3.157
201903 2.240 107.251 2.818
201906 1.953 108.070 2.438
201909 3.554 108.329 4.427
201912 3.232 108.420 4.022
202003 2.885 108.902 3.574
202006 5.462 108.767 6.776
202009 4.877 109.815 5.992
202012 4.383 109.897 5.381
202103 8.415 111.754 10.160
202106 7.978 114.631 9.390
202109 7.659 115.734 8.929
202112 7.091 117.630 8.134
202203 6.561 121.301 7.298
202206 5.993 125.017 6.468
202209 5.334 125.227 5.747
202212 4.974 125.222 5.359
202303 4.863 127.348 5.152
202306 4.443 128.729 4.657
202309 4.086 129.860 4.245
202312 3.735 129.419 3.894
202403 3.744 131.776 3.834
202406 3.487 132.554 3.549
202409 3.181 133.029 3.226
202412 2.798 133.157 2.835
202503 2.517 134.927 2.517

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Fate Therapeutics  (NAS:FATE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Fate Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.06/3.99
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Fate Therapeutics was 15.89. The lowest was 0.19. And the median was 1.22.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Fate Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Fate Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Executives
Bahram Valamehr officer: Chief Development Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Cindy Tahl officer: See Remarks C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Yuan Xu director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Dulac Edward J Iii officer: Chief Financial Officer FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
J Scott Wolchko director, officer: President and CEO C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Brian T. Powl officer: Chief Commercial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Yu-waye Chu officer: See Remarks FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
John Mendlein director
Mark Plavsic officer: Chief Technical Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karin Jooss director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Robert S Epstein director